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Inflammatory bowel disease (IBD) is becoming more common both in the Eastern and Western countries, and the increasing pattern is more rapid in children and adolescents than in the adult population. 1, 2 Compared to patient with late onset UC, those with pediatric onset UC tend to show more severe and widespread disease location at diagnosis and a high rate of disease extension during follow-up. 3, 4 In a population based European study, the 5-year colectomy rate was also higher among patients with pediatric onset UC (8.1%) than among patients with adult onset UC (4.1%). 5 As steroids have a variety of side effects, such as growth impairments, pediatricians are often reluctant to use steroids; however paradoxically the proportion of steroid-dependent or refractory colitis is also higher in the pediatric age group than in adults. 6 Although new effective drugs with various mechanisms have begun to be used in adult UC patients, many of these drugs are not approved for use in children or not covered by insurance in some countries. Hence, there are more restrictions on the use of new effective drugs for pediatric UC patients. In order to overcome these obstacles while managing pediatric IBD patients, it is important to optimize the currently available drugs or therapies. Tacrolimus, an immunomodulatory, which act as a potent inhibitor of helper-T lymphocytes, is known to be effective in adult UC 7 and was sugwww.irjournal.org reduced from 19.2 mg/day at the onset of tacrolimus administration to 5.7 mg/day at week 8 (P < 0.001), which reveals the steroid-sparing effect of tacrolimus administration. Although adverse events were identified during tacrolimus treatment in 36 patients (53.7%), most of the adverse events were mild and only 6 patients (9.0%) required discontinuation of tacrolimus owing to adverse events (renal impairment, myelosuppression, intestinal infection, and vomiting), which improved after discontinuation of tacrolimus or appropriate treatment.
These results suggest that appropriate use of tacrolimus is relatively safe in patients with pediatric UC and can be effective in a substantial number of patients with steroid-refractory or dependent UC, thus achieving steroid-sparing effects. However, as only a temporary effect is expected, efforts are required to connect subsequent treatments for the maintenance of remission. Further prospective studies are needed to establish the optimized strategy for using tacrolimus in the management of children and adolescent with UC.
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